All In Biotech

Drug Trial Radar · NCT06439563

Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers

A Multicenter, Parallel, Double-blind, Randomized, Active-controlled, Non-inferiority, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 Treatment in the Prevention of (NSAIDs)-Induced Peptic Ulcers

Last checked: Nov 19, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 364 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

364

Planned (sponsor's estimate)

Start

Oct 22, 2024

Primary completion

Aug 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Onconic Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jun 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The sutdy aims to to demonstrate the non-inferiority of JP-1366 10 mg compared to Lanston Capsule 15 mg in preventing NSAIDs-induced peptic ulcers and to compare/evaluate the efficacy and safety of JP-1366 10 mg.

Conditions

  • Peptic Ulcer

Interventions

  • JP-1366 10 mgDrug

    JP-1366 10 mg, tablet, orally once a day for up to 24 weeks

  • Lanston Capsule 15 mgDrug

    Lanston Capsule 15 mg orally once a day for up to 24 weeks

  • JP-1366 10 mg placeboDrug

    JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks

  • Lanston Capsule 15 mg placeboDrug

    Lanston Capsule 15 mg placebo, orally once a day for up to 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative proportion of subjects who developed peptic ulcersTime frame: at 24 weeks after administration of investigational products

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Konkuk University Medical Center

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.